CGON
CG Oncology, Inc. Common stock
NASDAQ: CGON · HEALTHCARE · BIOTECHNOLOGY
$64.75
-1.22% today
Updated 2026-04-29
Market cap
$5.70B
P/E ratio
—
P/S ratio
1,410.56x
EPS (TTM)
$-2.08
Dividend yield
—
52W range
$21 – $74
Volume
1.3M
CG Oncology, Inc. Common stock (CGON) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $10.36M | $191000.00 | $204000.00 | $1.14M | $4.04M |
| Revenue growth (YoY) | — | -98.2% | +6.8% | +458.3% | +254.7% |
| Cost of revenue | $10000.00 | $15000.00 | $17000.00 | $32000.00 | $4.65M |
| Gross profit | $10.35M | $176000.00 | $204000.00 | $1.14M | $-607000.00 |
| Gross margin | 99.9% | 92.1% | 100.0% | 100.0% | -15.0% |
| R&D | $18.32M | $29.03M | $45.75M | $82.10M | $116.64M |
| SG&A | $4.64M | $6.41M | $9.90M | $33.70M | $73.53M |
| Operating income | $-12.61M | $-35.25M | $-55.45M | $-114.67M | $-190.77M |
| Operating margin | -121.7% | -18453.4% | -27180.9% | -10067.3% | -4722.1% |
| EBITDA | $-12.38M | $-35.23M | $-55.43M | $-114.63M | $-159.55M |
| EBITDA margin | -119.5% | -18445.5% | -27172.5% | -10064.4% | -3949.3% |
| EBIT | $-12.39M | $-35.25M | $-55.45M | $-114.67M | $-161.00M |
| Interest expense | $451000.00 | $1000.00 | $6.90M | — | — |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-12.84M | $-35.44M | $-48.61M | $-88.04M | $-161.00M |
| Net income growth (YoY) | — | -176.1% | -37.1% | -81.1% | -82.9% |
| Profit margin | -124.0% | -18556.5% | -23827.0% | -7729.5% | -3985.0% |